Next Pharmaceutical Products (Pvt.) Ltd
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer developing and marketing branded medicines across multiple therapeutic categories.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Next Pharmaceutical Products (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 44 A-B, Sundar Industrial Estate, Lahore, Pakistan
- Website
- nextpharmaceutical.com ↗
- Phone
- +92 42 35297630-2
- info@nextpharco.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Linzanext | Linezolid | 600 mg | Tablet | 12's | 099172 | PKR 4,104.24 | PKR 342.02/tablet | 13% below median |
| Linzanext | Linezolid | 400 mg | Tablet | 12's | 099174 | PKR 2,344.36 | PKR 195.36/tablet | 17% below median |
| Loritanext | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 101928 | PKR 12,331.98 | PKR 102.77/tablet | 7% above median |
| Motizole | Metronidazole | 500 mg/100 mL | Injection | 100 ml | 104735 | PKR 111.54 | PKR 1.12/mL | 23% below median |
| Moxiflin 400 mg | Metronidazole | 400 mg/250 mL | IV infusion | 250 ml | 104737 | PKR 1,430.04 | PKR 5.72/mL | No comparator |
| Nexstan | Atorvastatin | 10 mg | Tablet | 10's | 108078 | PKR 206.23 | PKR 20.62/tablet | 27% below median |
| Nexstan | Atorvastatin | 20 mg | Tablet | 10's | 108079 | PKR 349.01 | PKR 34.90/tablet | 28% below median |
| NexstanSource observed | Atorvastatin | 40 mg | Tablet | 10's | 108080Official source ↗ | No indexed price | — | — |
| Nexstan 40 mg Tablet Each Film-Coated Tablet Contains: Atorvastatin as Calcium trihydrate... 30 mgSource observed | — | — | — | 10's | 108080Official source ↗ | No indexed price | — | — |
| Nextfol | Folic acid | 5 mg | Tablet | 100's | 099922 | PKR 84.33 | PKR 0.84/tablet | 5% above median |
| Nextfor | Metformin | 500 mg | Tablet | 50's | 099169 | PKR 110.34 | PKR 2.21/tablet | 19% below median |
| Nirober | Ribavirin | 200 mg | Capsule | 10's | 084495 | PKR 478.73 | PKR 47.87/capsule | Near median |
| Nuskid | Cefepime | 500 mg | IM/IV injection | 1's | 104731 | PKR 393.26 | PKR 393.26/vial/unit | No comparator |
| Nuskid 1000mg IV/IM InjectionRegistry verified | Cefepime as HCl with L-Arginine | — | — | — | 104732Official source ↗ | No indexed price | — | — |
| Omecap | Omeprazole | 20 mg | Capsule | 20X7's | 084493 | PKR 2,779.51 | PKR 19.85/capsule | Near median |
| Omecap | Omeprazole | 20 mg | Capsule | 14's | 084493 | PKR 287.23 | PKR 20.52/capsule | Near median |
| Omecap | Omeprazole | 40 mg | Capsule | 14's | 084494 | PKR 498.68 | PKR 35.62/capsule | Near median |
| Oseltanext | Oseltamivir | 75 mg | Capsule | 10's | 101930 | PKR 1,204.29 | PKR 120.43/capsule | Near median |
| Paranext | Paracetamol | 500 mg | Tablet | 200's | 084484 | PKR 705.01 | PKR 3.53/tablet | Near median |
| Paranext | Paracetamol | 120 mg | Suspension | 100 ml | 084505 | PKR 76.12 | PKR 0.76/mL | 27% below median |
| Paranext | Paracetamol | 120 mg/5 mL | Suspension | 100ml | 084505 | PKR 110.02 | PKR 1.10/mL | Near median |
| Paranext | Paracetamol | 120 mg/5 mL | Suspension | 60 ml | 084505 | PKR 54.75 | PKR 0.91/mL | 13% below median |
| Paranext | Paracetamol | 120 mg/5 mL | Suspension | 60ml | 084505 | PKR 66.01 | PKR 1.10/mL | Near median |
| Paranext | Paracetamol | 250 mg/5 mL | Suspension | 60ml | 084506 | PKR 94.97 | PKR 1.58/mL | Near median |
| Paranext | Paracetamol | 250 mg/5 mL | Suspension | 60 ml | 084506 | PKR 70.30 | PKR 1.17/mL | 24% below median |
| Paranext | Paracetamol | 250 mg/5 mL | Suspension | 90ml | 084506 | PKR 103.28 | PKR 1.15/mL | 25% below median |
| Ribane | Ribavirin | 400 mg | Tablet | 50's | 084485 | PKR 825.81 | PKR 16.52/tablet | 8% below median |
| Ribane | Ribavirin | 400 mg | Tablet | 10's | 084485 | PKR 179.53 | PKR 17.95/tablet | Near median |
| Ribane | Ribavirin | 400 mg | Tablet | 30's | 084485 | PKR 496.68 | PKR 16.56/tablet | 8% below median |
| Silvanext | Sulphadiazine | 1% | Cream | 50gm | 095600 | PKR 222.85 | PKR 4.46/g | 12% below median |
| Silvanext | Sulphadiazine | 1% | Cream | 15gm | 095600 | PKR 75.96 | PKR 5.06/g | 9% above median |
| Sulbanext 1g IV/IM InjectionRegistry verified | Cefoperazone sodium eq to Cefoperazone, Sulbactum sodium eq to sulbactam | — | — | — | 104733Official source ↗ | No indexed price | — | — |
| Sulbanext 2g IV/IM InjectionRegistry verified | Cefoperazone sodium eq to Cefoperazone, Sulbactum sodium eq to sulbactam | — | — | — | 104741Official source ↗ | No indexed price | — | — |
| Velvet-plus | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 160 mg + 25 mg | Tablet | 14's | 106614 | PKR 238.98 | PKR 17.07/tablet | 7% below median |
| Velvet-plus | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 160 mg + 12.5 mg | Tablet | 14's | 106615 | PKR 217.97 | PKR 15.57/tablet | 7% below median |
| Velvet-plus | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 160 mg + 25 mg | Tablet | 14's | 106616 | PKR 223.23 | PKR 15.95/tablet | 7% below median |
| Velvet-plus | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 320 mg + 25 mg | Tablet | 14's | 106617 | PKR 367.67 | PKR 26.26/tablet | Near median |
| Velvet-plus | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 160 mg + 12.5 mg | Tablet | 14's | 108083 | PKR 236.36 | PKR 16.88/tablet | 7% below median |
| Velvet-plus 10 | Amlodipine | 25 mg | Tablet | 28's | 106614 | PKR 477.97 | PKR 17.07/tablet | 7% above median |
| Velvet-plus 10 | Amlodipine | 12.5 mg | Tablet | 28's | 108083 | PKR 472.71 | PKR 16.88/tablet | Near median |
| Velvet-plus 5 | Amlodipine | 12.5 mg | Tablet | 28's | 106615 | PKR 435.95 | PKR 15.57/tablet | 9% below median |
| Velvet-plus 5 | Amlodipine | 25 mg | Tablet | 28's | 106616 | PKR 446.45 | PKR 15.94/tablet | 7% below median |
| Verinoxa | Rivaroxaban | 10 mg | Tablet | 30's | 095696 | PKR 15,464.48 | PKR 515.48/tablet | 7% below median |
| Verinoxa | Rivaroxaban | 10 mg | Tablet | 10's | 095696 | PKR 5,262.16 | PKR 526.22/tablet | Near median |
| Verinoxa | Rivaroxaban | 15 mg | Tablet | 7's | 095697 | PKR 4,951.89 | PKR 707.41/tablet | Near median |
| Verinoxa | Rivaroxaban | 15 mg | Tablet | 10's | 095697 | PKR 6,719.16 | PKR 671.92/tablet | Near median |
| Verinoxa | Rivaroxaban | 15 mg | Tablet | 14's | 095697 | PKR 9,406.83 | PKR 671.92/tablet | Near median |
| Verinoxa | Rivaroxaban | 20 mg | Tablet | 7's | 095698 | PKR 6,266.60 | PKR 895.23/tablet | Near median |
| Verinoxa | Rivaroxaban | 20 mg | Tablet | 10's | 095698 | PKR 8,505.66 | PKR 850.57/tablet | Near median |
| Verinoxa | Rivaroxaban | 20 mg | Tablet | 14's | 095698 | PKR 11,907.93 | PKR 850.57/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.